AI Buyer Insights:

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Michelin, an e2open customer evaluated Oracle Transportation Management

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Michelin, an e2open customer evaluated Oracle Transportation Management

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

List of TreeAge Pro Healthcare Customers

Apply Filters For Customers

Logo Customer Industry Empl. Revenue Country Vendor Application Category When SI Insight
Cleveland Clinic Healthcare 10 $1M United States TreeAge TreeAge Pro Healthcare Analytics and BI 2021 n/a
In 2021, Cleveland Clinic researchers used TreeAge Pro Healthcare to conduct HEOR modeling for a multi-center economic evaluation documented in the MENTOR study. TreeAge Pro Healthcare, an Analytics and BI application, was used to construct Markov models assessing cost-effectiveness of rituximab versus cyclosporine. Implementation centered on model construction and analysis workflows typical to clinical-economics research, with TreeAge Pro Healthcare used to define health states, transition probabilities, cost inputs, and quality-adjusted life year outputs. The application supported calculation of incremental cost-effectiveness ratios and both probabilistic and deterministic sensitivity analyses consistent with health economic evaluation practice. Operational scope referenced researchers affiliated with Cleveland Clinic as co-investigators in the multi-center MENTOR study within the United States healthcare context, and the paper records TreeAge Pro use in the methods section. Deployment was research-focused to support HEOR and clinical-economics functions for the study team rather than an enterprise administrative rollout. The published HEOR analysis reported rituximab as cost-effective, presenting an incremental cost-effectiveness ratio of approximately $8,373 per QALY in the model results, with TreeAge Pro cited in the methods. Reporting and model disclosure in the publication align with standard academic governance for reproducibility and methodological transparency in economic modeling.
NHS Scotland Government 140000 $21.6B United Kingdom TreeAge TreeAge Pro Healthcare Analytics and BI 2021 n/a
In 2021, NHS Scotland used TreeAge Pro Healthcare to build decision-tree and health-economic models evaluating genomic testing strategies for rare developmental disorders from an NHS Scotland perspective. TreeAge Pro Healthcare is an Analytics and BI application and the cited work references TreeAge Pro 2021 module usage to construct probabilistic cost models and scenario analyses for diagnostic pathways. Modeling focused on explicit decision-tree health-economic constructs, including pathway branching for testing strategies, cost inputs, and outcome nodes reflecting diagnostic yield and downstream resource use. The implementation leveraged TreeAge Pro Healthcare features for deterministic and probabilistic sensitivity analysis to compare trio exome sequencing as a second-line test against extended diagnostic odysseys, reflecting standard capabilities in decision-analytic and cost-effectiveness workflows. Operational coverage was centered in the Scotland health economics and genomics evaluation context, supporting clinical genetics, health economics, and policy review teams within NHS Scotland. No external system integrations are documented in the source, the work is presented as a stand‑alone modeling exercise performed from an NHS Scotland perspective. Governance and use case framing were oriented to health technology assessment style review, with models produced to inform testing policy options. The published outcome from the TreeAge Pro Healthcare 2021 models found that offering trio exome sequencing as a second-line test was cost-saving versus the diagnostic odyssey, a result used to evaluate genomic testing strategy options.
University Health Network Healthcare 17938 $2.8B Canada TreeAge TreeAge Pro Healthcare Analytics and BI 2020 n/a
In 2020 University Health Network deployed TreeAge Pro Healthcare version 2020 R1.1 as part of an Analytics and BI implementation to support health economic modeling for a Canada based clinical decision support and HEOR study. Analysts at UHN used TreeAge Pro Healthcare to construct individual level Markov models that evaluated preoperative obstructive sleep apnea screening strategies, explicitly citing the software in the methods of the published study. The implementation centered on individual level Markov modeling and lifetime horizon cost effectiveness workflows, leveraging TreeAge Pro Healthcare capabilities for decision analytic modeling and model documentation. Models were configured to represent sequential screening pathways, in this case STOP Bang followed by polysomnography, and to support interpretive outputs required for cost effectiveness assessment and policy oriented HEOR reporting. Operational scope covered HEOR analysts and clinical decision support stakeholders within UHN, with modeling work scoped to Canadian clinical and payer perspectives for preoperative screening. The use of TreeAge Pro Healthcare informed internal evaluation of screening strategy trade offs and provided reproducible model artifacts suitable for peer reviewed publication. Governance for the effort is reflected in the methods citation, indicating the modeling approach and software choice were part of the study protocol and reproducibility controls. The published study concluded that STOP Bang followed by polysomnography was cost effective on a lifetime horizon, and TreeAge Pro Healthcare is explicitly named as the analytic engine used in the research.
Showing 1 to 3 of 3 entries

Buyer Intent: Companies Evaluating TreeAge Pro Healthcare

ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating TreeAge Pro Healthcare. Gain ongoing access to real-time prospects and uncover hidden opportunities.

Discover Software Buyers actively Evaluating Enterprise Applications

Logo Company Industry Employees Revenue Country Evaluated
No data found
FAQ - APPS RUN THE WORLD TreeAge Pro Healthcare Coverage

TreeAge Pro Healthcare is a Analytics and BI solution from TreeAge.

Companies worldwide use TreeAge Pro Healthcare, from small firms to large enterprises across 21+ industries.

Organizations such as NHS Scotland, University Health Network and Cleveland Clinic are recorded users of TreeAge Pro Healthcare for Analytics and BI.

Companies using TreeAge Pro Healthcare are most concentrated in Government and Healthcare, with adoption spanning over 21 industries.

Companies using TreeAge Pro Healthcare are most concentrated in United Kingdom, Canada and United States, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of TreeAge Pro Healthcare across Americas, EMEA, and APAC.

Companies using TreeAge Pro Healthcare range from small businesses with 0-100 employees - 33.33%, to mid-sized firms with 101-1,000 employees - 0%, large organizations with 1,001-10,000 employees - 0%, and global enterprises with 10,000+ employees - 66.67%.

Customers of TreeAge Pro Healthcare include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.

Contact APPS RUN THE WORLD to access the full verified TreeAge Pro Healthcare customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Analytics and BI.